Indofarma tbk (INAF)’s target sales is to reach 1,9 trillion IDR, or to increase by 17% this year compared to 2015’s achievement. But, on the first term of this year, INAF just reached 24,8% of its target. Moreover, the company has been recording losses although their target is to achieve the improvement in the bottom-line by cutting the number of employees.
However, these losses often occur on the first term of the year, as it did in 2015. By the end of last year, INAF was able fix the records back into profit. Hopefully, the same will happen again this year. This happened because the record of half-year revenue was only 25% of the income year, while the costs were charged according to the time.
Meanwhile, the other pharmacies issuers’ apparently show a steady growth with an average of 13,6% and profit growth by 7,2%. The highest growth happened on Kimia Farma Tbk (KAEF) with almost all of the product lines experiencing growth.
On the other hand, Tempo Scan Pacific Tbk (TSPC) had experienced the decrease of net profit although their revenue had risen. This happened when the increase in sales expenses were higher than the increase in sales. As a result, TSPC’s profit is pressured. Besides, TSPC’s increasing revenue in cosmetic products and distribution services is quiet high which is by 18%.
Add Comment